We analyzed whether variants or co-occurring mutations influence the outcome of AKL TKI treatment in ALK+ non-small-cell lung cancer (NSCLC). Between March 2017 and October 2018, 489 NSCLC tumor specimens were examined with OncoPanel AMC version3 which is a NGS based assay for the detection of single-nucleotide variants, insertions, deletions, copy number alterations and structural variants across 382 genes. 43 patients were identified as having ALK rearrangement. And 37 patients received ALK TKI treatment. Progression free survival (PFS) and overall survival (OS) were analyzed respectively according to ALK variants and other co-occuring mutations. We found that in ALK+ NSCLC, having co-occurring CDKN2A/2B alteration was associated with a poorer OS when treated with an anti-ALK agent. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1204
Authors: J.Y. Ha, S. Yoon, D.H. Lee, J. Choi, S. Kim